272 related articles for article (PubMed ID: 31175826)
1. Barriers to accrual and enrollment in brain tumor trials.
Lee EQ; Chukwueke UN; Hervey-Jumper SL; de Groot JF; Leone JP; Armstrong TS; Chang SM; Arons D; Oliver K; Verble K; Musella A; Willmarth N; Alexander BM; Bates A; Doherty L; Galanis E; Gaffey S; Halkin T; Friday BE; Fouladi M; Lin NU; Macdonald D; Mehta MP; Penas-Prado M; Vogelbaum MA; Sahebjam S; Sandak D; van den Bent M; Weller M; Reardon DA; Wen PY
Neuro Oncol; 2019 Sep; 21(9):1100-1117. PubMed ID: 31175826
[TBL] [Abstract][Full Text] [Related]
2. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
Lee EQ; Weller M; Sul J; Bagley SJ; Sahebjam S; van den Bent M; Ahluwalia M; Campian JL; Galanis E; Gilbert MR; Holdhoff M; Lesser GJ; Lieberman FS; Mehta MP; Penas-Prado M; Schreck KC; Strowd RE; Vogelbaum MA; Walbert T; Chang SM; Nabors LB; Grossman S; Reardon DA; Wen PY
Neuro Oncol; 2020 May; 22(5):601-612. PubMed ID: 31974566
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.
Lara PN; Higdon R; Lim N; Kwan K; Tanaka M; Lau DH; Wun T; Welborn J; Meyers FJ; Christensen S; O'Donnell R; Richman C; Scudder SA; Tuscano J; Gandara DR; Lam KS
J Clin Oncol; 2001 Mar; 19(6):1728-33. PubMed ID: 11251003
[TBL] [Abstract][Full Text] [Related]
4. Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.
Budhu JA; Chukwueke UN; Jackson S; Lee EQ; McFaline-Figueroa JR; Willmarth N; Dalmage M; Kawachi I; Arons D; Chang SM; Galanis E; Hervey-Jumper SL; Wen PY; Porter AB
Neuro Oncol; 2024 Apr; 26(4):596-608. PubMed ID: 38071654
[TBL] [Abstract][Full Text] [Related]
5. Effect of medical oncologists' attitudes on accrual to clinical trials in a community setting.
Somkin CP; Ackerson L; Husson G; Gomez V; Kolevska T; Goldstein D; Fehrenbacher L
J Oncol Pract; 2013 Nov; 9(6):e275-83. PubMed ID: 24151327
[TBL] [Abstract][Full Text] [Related]
6. Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers.
Knelson LP; Cukras AR; Savoie J; Agarwal A; Guo H; Hu J; Fell G; Lederman R; Hughes ME; Winer EP; Lin NU; Tolaney SM
Clin Breast Cancer; 2020 Oct; 20(5):395-401.e3. PubMed ID: 32605813
[TBL] [Abstract][Full Text] [Related]
7. Provider-reported challenges and barriers to referring patients to neuro-oncology clinical trials: a report from the Society for Neuro-Oncology member survey.
Rogers JL; Acquaye A; Vera E; Bates A; Wen PY; Armstrong TS
Neurooncol Pract; 2020 Jan; 7(1):38-51. PubMed ID: 32257283
[TBL] [Abstract][Full Text] [Related]
8. Imaging Criteria in Neuro-oncology.
Nowosielski M; Wen PY
Semin Neurol; 2018 Feb; 38(1):24-31. PubMed ID: 29548049
[TBL] [Abstract][Full Text] [Related]
9. Response Assessment in Neuro-Oncology Clinical Trials.
Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial discussion, referral, and recruitment: physician, patient, and system factors.
Kaplan CP; Nápoles AM; Dohan D; Shelley Hwang E; Melisko M; Nickleach D; Quinn JA; Haas J
Cancer Causes Control; 2013 May; 24(5):979-88. PubMed ID: 23420328
[TBL] [Abstract][Full Text] [Related]
11. Organizational and physician factors associated with patient enrollment in cancer clinical trials.
Jacobs SR; Weiner BJ; Reeve BB; Weinberger M; Minasian LM; Good MJ
Clin Trials; 2014 Oct; 11(5):565-75. PubMed ID: 24902923
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Brain Tumor Response: RANO and Its Offspring.
Eisele SC; Wen PY; Lee EQ
Curr Treat Options Oncol; 2016 Jul; 17(7):35. PubMed ID: 27262709
[TBL] [Abstract][Full Text] [Related]
13. African-American patients with cancer Talking About Clinical Trials (TACT) with oncologists during consultations: evaluating the efficacy of tailored health messages in a randomised controlled trial-the TACT study protocol.
Brown RF; Davis R; Wilson Genderson M; Grant S; Cadet D; Lessard M; Alpert J; Ward J; Ginder G
BMJ Open; 2016 Dec; 6(12):e012864. PubMed ID: 27986738
[TBL] [Abstract][Full Text] [Related]
14. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.
Kickingereder P; Isensee F; Tursunova I; Petersen J; Neuberger U; Bonekamp D; Brugnara G; Schell M; Kessler T; Foltyn M; Harting I; Sahm F; Prager M; Nowosielski M; Wick A; Nolden M; Radbruch A; Debus J; Schlemmer HP; Heiland S; Platten M; von Deimling A; van den Bent MJ; Gorlia T; Wick W; Bendszus M; Maier-Hein KH
Lancet Oncol; 2019 May; 20(5):728-740. PubMed ID: 30952559
[TBL] [Abstract][Full Text] [Related]
15. Barriers to Pediatric Oncologist Enrollment of Adolescents and Young Adults on a Cross-Network National Clinical Trials Network Supportive Care Cancer Clinical Trial.
Mittal N; Langevin AM; Kyono W; Dickens DS; Grimes A; Salsman JM; Pollock BH; Roth M
J Adolesc Young Adult Oncol; 2022 Feb; 11(1):117-121. PubMed ID: 33983848
[TBL] [Abstract][Full Text] [Related]
16. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
Nayak L; DeAngelis LM; Brandes AA; Peereboom DM; Galanis E; Lin NU; Soffietti R; Macdonald DR; Chamberlain M; Perry J; Jaeckle K; Mehta M; Stupp R; Muzikansky A; Pentsova E; Cloughesy T; Iwamoto FM; Tonn JC; Vogelbaum MA; Wen PY; van den Bent MJ; Reardon DA
Neuro Oncol; 2017 May; 19(5):625-635. PubMed ID: 28453751
[TBL] [Abstract][Full Text] [Related]
17. Thoracic Radiation Oncology Clinical Trial Accrual and Reasons for Nonenrollment: Results of a Large, Prospective, Multiyear Analysis.
Mesko S; Ning MS; Lakomy D; Verma V; Chang JY; O'Reilly M; Jeter MD; Gandhi SJ; Lin SH; Nguyen QN; Liao Z; Welsh J; Chen AB; Hahn S; Gomez DR
Int J Radiat Oncol Biol Phys; 2020 Aug; 107(5):897-908. PubMed ID: 32360653
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California.
Martel CL; Li Y; Beckett L; Chew H; Christensen S; Davies A; Lam KS; Lau DH; Meyers FJ; O'donnell RT; Richman C; Scudder S; Tanaka M; Tuscano J; Welborn J; Wun T; Gandara DR; Lara PN
Cancer J; 2004; 10(5):294-300. PubMed ID: 15530258
[TBL] [Abstract][Full Text] [Related]
19. Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative.
Pinto HA; McCaskill-Stevens W; Wolfe P; Marcus AC
Ann Epidemiol; 2000 Nov; 10(8 Suppl):S78-84. PubMed ID: 11189096
[TBL] [Abstract][Full Text] [Related]
20. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
